BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 35996066)

  • 1. A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting.
    McCloskey C; Ortega MT; Nair S; Garcia MJ; Manevy F
    Pharmacoecon Open; 2023 Jan; 7(1):3-36. PubMed ID: 35996066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. White Paper on the Value of Time Savings for Patients and Healthcare Providers of Breast Cancer Therapy: The Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Injection as an Example.
    Jackisch C; Manevy F; Frank S; Roberts N; Shafrin J
    Adv Ther; 2022 Feb; 39(2):833-844. PubMed ID: 34988876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection plus chemotherapy in HER2-positive early breast cancer (FeDeriCa): a randomised, open-label, multicentre, non-inferiority, phase 3 study.
    Tan AR; Im SA; Mattar A; Colomer R; Stroyakovskii D; Nowecki Z; De Laurentiis M; Pierga JY; Jung KH; Schem C; Hogea A; Badovinac Crnjevic T; Heeson S; Shivhare M; Kirschbrown WP; Restuccia E; Jackisch C;
    Lancet Oncol; 2021 Jan; 22(1):85-97. PubMed ID: 33357420
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive breast cancer: A multidisciplinary approach.
    DuMond B; Patel V; Gross A; Fung A; Weber S
    J Oncol Pharm Pract; 2021 Jul; 27(5):1214-1221. PubMed ID: 33719721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and severity of anaphylaxis and hypersensitivity in trials of intravenous pertuzumab plus trastuzumab or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection for HER2-positive breast cancer.
    Swain SM; Tan AR; Gianni L; Kuemmel S; Dang CT; Schneeweiss A; O'Shaughnessy J; Liu H; Aguila C; Heeson S; Macharia H; Yang K; Restuccia E; Loibl S
    Eur J Cancer; 2023 Jan; 178():70-81. PubMed ID: 36410207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting.
    Olofsson S; Norrlid H; Karlsson E; Wilking U; Ragnarson Tennvall G
    Breast; 2016 Oct; 29():140-6. PubMed ID: 27498127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study.
    O'Shaughnessy J; Sousa S; Cruz J; Fallowfield L; Auvinen P; Pulido C; Cvetanovic A; Wilks S; Ribeiro L; Burotto M; Klingbiel D; Messeri D; Alexandrou A; Trask P; Fredriksson J; Machackova Z; Stamatovic L;
    Eur J Cancer; 2021 Jul; 152():223-232. PubMed ID: 34147014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic and exploratory exposure-response analysis of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer in the FeDeriCa study.
    Wang B; Deng R; Hennig S; Badovinac Crnjevic T; Kaewphluk M; Kågedal M; Quartino AL; Girish S; Li C; Kirschbrown WP
    Cancer Chemother Pharmacol; 2021 Sep; 88(3):499-512. PubMed ID: 34106303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous trastuzumab (Herceptin) versus intravenous trastuzumab for the treatment of patients with HER2-positive breast cancer: A time, motion and cost assessment study in a lean operating day care oncology unit.
    Tjalma WAA; Van den Mooter T; Mertens T; Bastiaens V; Huizing MT; Papadimitriou K
    Eur J Obstet Gynecol Reprod Biol; 2018 Feb; 221():46-51. PubMed ID: 29245056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.
    North RT; Harvey VJ; Cox LC; Ryan SN
    Clinicoecon Outcomes Res; 2015; 7():423-30. PubMed ID: 26251623
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential cost savings owing to the route of administration of oncology drugs: a microcosting study of intravenous and subcutaneous administration of trastuzumab and rituximab in the Netherlands.
    Franken MG; Kanters TA; Coenen JL; de Jong P; Koene HR; Lugtenburg PJ; Jager A; Uyl-de Groot CA
    Anticancer Drugs; 2018 Sep; 29(8):791-801. PubMed ID: 29846248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
    Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
    Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The challenge of sustainability in healthcare systems: economic and organizational impact of subcutaneous formulations for rituximab and trastuzumab in onco-hematology.
    Altini M; Gentili N; Balzi W; Musuraca G; Maltoni R; Masini C; Galardi F; Bertoni L; Massa I
    Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):503-509. PubMed ID: 32403958
    [No Abstract]   [Full Text] [Related]  

  • 15. Potential resource and cost saving analysis of subcutaneous versus intravenous administration for rituximab in non-Hodgkin's lymphoma and for trastuzumab in breast cancer in 17 Italian hospitals based on a systematic survey.
    Ponzetti C; Canciani M; Farina M; Era S; Walzer S
    Clinicoecon Outcomes Res; 2016; 8():227-33. PubMed ID: 27284260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the economic benefits, administration times, and patient preferences associated with the use of biotechnological drugs administered subcutaneously and intravenously in patients with cancer: a systematic review.
    Parra A; Hernández C; Prieto-Pinto L
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(9):1017-1026. PubMed ID: 37665685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland.
    O'Brien GL; O'Mahony C; Cooke K; Kinneally A; Sinnott SJ; Walshe V; Mulcahy M; Byrne S
    Clin Breast Cancer; 2019 Jun; 19(3):e440-e451. PubMed ID: 30853347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain.
    Lopez-Vivanco G; Salvador J; Diez R; López D; De Salas-Cansado M; Navarro B; De la Haba-Rodríguez J
    Clin Transl Oncol; 2017 Dec; 19(12):1454-1461. PubMed ID: 28577152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer.
    Rojas L; Muñiz S; Medina L; Peña J; Acevedo F; Pinto MP; Sanchez C
    PLoS One; 2020; 15(2):e0227961. PubMed ID: 32023267
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.